title: Treatment of clozapine-associated weight gain: a systematic review.
abstract: OBJECTIVE
  Clozapine is an antipsychotic drug with superior efficacy in treatment-resistant schizophrenia. Clozapine is associated with a low likelihood of extrapyramidal symptoms and other neurological side-effects but a high propensity to induce weight gain and general metabolic dysregulation. Various pharmacological and behavioral treatment approaches for reducing clozapine-associated weight gain exist in the literature; however, there are currently no clear clinical guidelines as to which method is preferred. The aim of the current review is to systematically summarize studies that have studied both pharmacological and non-pharmacological interventions to attenuate or reverse clozapine-associated weight gain.
  
  
  METHODS
  A systematic review of EMBASE and MEDLINE databases of all articles published prior to January 2014 was conducted. Seventeen studies were identified as meeting inclusion criteria and included in the review.
  
  
  RESULTS
  Aripiprazole, fluvoxamine, metformin, and topiramate appear to be beneficial; however, available data are limited to between one and three randomized controlled trials per intervention. Orlistat shows beneficial effects, but in males only. Behavioral and nutritional interventions also show modest effects on decreasing clozapine-associated weight gain, although only a small number of such studies exist.
  
  
  CONCLUSIONS
  While a number of pharmacological interventions can produce modest weight loss, each may be associated with negative side effects, which should be considered before beginning treatment. Given the pressing need to improve cardiometabolic health in most clozapine-treated patients, substantially more research is needed to develop sound clinical practice guidelines for the treatment of clozapine-associated weight gain.
authors: Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada.
authors: Z
authors: Z
authors: Whitney
authors: R M
authors: RM
authors: Procyshyn
authors: D H
authors: DH
authors: Fredrikson
authors: A M
authors: AM
authors: Barr
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012559:Schizophrenia / Q000188:drug therapy; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D003024:Clozapine
references: JAMA. 1999 Jan 20;281(3):235-42
references: 9918478
references: Int J Neuropsychopharmacol. 2010 Sep;13(8):1115-25
references: 20459883
references: Clin Ther. 2004 May;26(5):649-66
references: 15220010
references: Clin Schizophr Relat Psychoses. 2012 Oct;6(3):134-44
references: 23006238
references: Synapse. 1996 Dec;24(4):349-94
references: 10638826
references: Expert Opin Emerg Drugs. 2014 Dec;19(4):511-31
references: 25234340
references: Can J Psychiatry. 2007 Jun;52(6 Suppl 1):59S-70S
references: 17824353
references: CNS Drugs. 2011 Dec 1;25(12):1035-59
references: 22133326
references: Acta Psychiatr Scand. 2008 Jul;118(1):4-18
references: 18498432
references: J Clin Psychiatry. 2002;63 Suppl 12:50-5
references: 12562062
references: Neuropsychopharmacology. 2010 Jun;35(7):1520-30
references: 20336059
references: Epilepsy Res. 2011 Aug;95(3):189-99
references: 21684121
references: Compr Psychiatry. 1999 Nov-Dec;40(6):407-14
references: 10579370
references: Acta Psychiatr Scand. 2007 Feb;115(2):101-5
references: 17244173
references: Acta Psychiatr Scand. 2006 Feb;113(2):142-7
references: 16423166
references: Clin Schizophr Relat Psychoses. 2011 Apr;5(1):17-25
references: 21459735
references: Pharmacol Ther. 2010 Jan;125(1):169-79
references: 19931306
references: Postgrad Med. 2008 Jul;120(2):18-33
references: 18654065
references: J Clin Psychiatry. 2013 May;74(5):e424-30
references: 23759461
references: Int J Neuropsychopharmacol. 2012 Oct;15(9):1351-71
references: 22339930
references: J Clin Psychiatry. 2004 Jun;65(6):766-71
references: 15291653
references: Ann Clin Psychiatry. 2010 Feb;22(1):33-42
references: 20196981
references: Rev Bras Psiquiatr. 2014 Oct-Dec;36(4):358
references: 25517419
references: Pharmacopsychiatry. 1999 Jul;32(4):148-53
references: 10505485
references: Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):945-54
references: 20452386
references: Am J Psychiatry. 1992 Jan;149(1):68-72
references: 1728188
references: Aust N Z J Psychiatry. 2006 Sep;40(9):810-4
references: 16911758
references: Expert Opin Pharmacother. 2005 Dec;6(15):2727-40
references: 16316311
references: Br J Psychiatry. 1997 Dec;171:502-8
references: 9519087
references: Schizophr Res. 2009 Aug;113(1):19-26
references: 19515536
references: Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:170-6
references: 24140931
references: Br J Psychiatry. 2008 Aug;193(2):101-7
references: 18669990
references: J Psychiatry Neurosci. 2009 Nov;34(6):433-42
references: 19949719
references: Biol Psychiatry. 2001 Dec 1;50(11):898-911
references: 11743944
references: J Clin Psychiatry. 2011 Mar;72 (3):326-30
references: 20816037
references: Schizophr Res. 2003 Jan 1;59(1):19-27
references: 12413638
references: J Clin Psychopharmacol. 2010 Dec;30(6):706-10
references: 21105286
references: CNS Drugs. 2005;19 Suppl 1:1-93
references: 15998156
references: Exp Clin Psychopharmacol. 2013 Apr;21(2):164-71
references: 23356730
references: BMC Psychiatry. 2014 Sep 12;14:253
references: 25227719
references: Trends Pharmacol Sci. 2010 Oct;31(10):484-97
references: 20674990
references: Psychiatr Serv. 2007 Apr;58(4):544-50
references: 17412858
references: Child Adolesc Psychiatr Clin N Am. 2012 Oct;21(4):941-55
references: 23040908
references: Hum Psychopharmacol. 2009 Apr;24(3):225-32
references: 19283774
references: Neuropsychiatr Dis Treat. 2011;7:135-49
references: 21552316
references: Pharmacol Res. 2010 Sep;62(3):187-206
references: 20416377
references: J Psychiatry Neurosci. 2012 Nov;37(6):407-15
references: 22640703
references: Lancet. 2008 Mar 29;371(9618):1085-97
references: 18374841
references: Harv Rev Psychiatry. 2003 Sep-Oct;11(5):230-44
references: 14555424
references: Diab Vasc Dis Res. 2008 Sep;5(3):157-67
references: 18777488
references: Int J Clin Pract. 2007 Aug;61(8):1356-70
references: 17627711
references: Pharmacol Ther. 2012 Aug;135(2):113-22
references: 22565090
references: Lancet. 2009 Jan 3;373(9657):31-41
references: 19058842
references: Expert Opin Drug Saf. 2010 Jul;9(4):623-31
references: 20367527
references: Schizophr Res. 2005 Dec 1;80(1):19-32
references: 16137860
references: J Res Med Sci. 2014 Jul;19(7):658-64
references: 25364368
references: Schizophr Res. 2011 Aug;130(1-3):53-6
references: 21565464
references: J Clin Psychiatry. 2008 May;69(5):706-11
references: 18426261
references: CNS Drugs. 2008;22(6):477-95
references: 18484791
references: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005148
references: 17253540
references: Endocrine. 2000 Oct;13(2):193-9
references: 11186220
references: J Clin Psychiatry. 2002 Apr;63(4):345-8
references: 12000209
references: PLoS Med. 2005 May;2(5):e141
references: 15916472
references: J Clin Psychiatry. 2010 May;71(5):566-73
references: 20361903
references: Drugs. 2008;68(13):1803-39
references: 18729534
references: Schizophr Res. 2012 Sep;140(1-3):204-13
references: 22831769
references: World Health Organ Tech Rep Ser. 1985;724:1-206
references: 3937340
references: Biomed Res Int. 2014;2014:656370
references: 24995318
references: JAMA. 2001 Aug 22-29;286(8):930-5
references: 11509057
references: J Psychopharmacol. 2009 Mar;23(2):157-62
references: 18515465